TNF inhibitors pose ‘modest risk’ for new-onset psoriasis

Patients with immune mediated diseases and treated with tumor necrosis factor-alpha inhibitors have a modest risk for new onset psoriasis, according to a study.“Biologics are in most cases effective, and the majority of adverse effects are mild and easy to manage. Paradoxically, psoriasis develops in a number of patients during tumor necrosis factor-alpha inhibition (TNFi) treatment,” David Thein, MB, of the department of dermatology at the University of Copenhagen and Copenhagen Research Group for Inflammatory Skin, and colleagues wrote.A cohort study of 109,085 patients withRead More

Categories: News

Related Articles

TNF inhibitors less effective for older-onset IBD patients

Anti-tumor necrosis factor therapy had reduced efficacy and safety for bio-naive patients with older-onset inflammatory bowel disease compared with younger patients, according to a study…

Two COVID-19 vaccine doses ‘highly effective’ in immune-mediated inflammatory disease

A two-dose vaccine course is “highly effective” against COVID-19 infection and severe outcomes in patients with rheumatoid arthritis, ankylosing spondylitis, psoriasis and inflammatory bowel disease,…

Biologics linked to lower dementia rate in older patients with IBD

SAN DIEGO — Older patients with inflammatory bowel disease who were treated with biologics exhibited a lower incidence of dementia compared with those never treated…

2019 Telehealth Bill

In 2019, Florida passed the Telehealth Bill which establishes standards of practice for telehealth services, including patient evaluations, record-keeping, and controlled substances prescribing. The bill…

Justin Bouck July 9, 2019

Anti-TNF, surgical closure induces long-term healing in Crohn’s fistulas

Short-term anti-tumor necrosis factor treatment combined with surgical closure induced long-term MRI healing in patients with Crohn’s perianal fistulas more frequently than anti-TNF therapy alone,…